Search Results
Nov 03, 2025, 10:35 ET Answer ALS Completes Release of Full Dataset and Integrates ALS TDI ARC Study Data into Neuromine
detailed clinical histories and outcomes. These data are linked with patient-derived biosamples and induced pluripotent stem cell (iPSC) lines, offering scientists a 360-degree view of each patient's ALS biology. All information is openly accessible through Neuromine, Answer ALS's cloud-based
More news about: Answer ALS
Oct 31, 2025, 09:00 ET Zhimeng Biopharma's investigational drug CB03-154 for amyotrophic lateral sclerosis has achieved the first patient first dose milestone in the phase 2/3 pivotal clinical trial.
CB03-154 has superior selectivity and stability. In vitro studies have confirmed that CB03-154 can significantly reduce the excessive excitation of iPSC motor neurons from ALS patients. Moreover, in the SOD-1 ALS transgenic mouse model, daily oral administration of CB03-154 (10 mg/kg) can effectively
More news about: Shanghai Zhimeng Biopharma Inc.
Oct 24, 2025, 13:02 ET Sampled and AutoGen Announce Partnership for Specialized Nucleic Acid Extraction and Multiomic Workflows
internally as part of its integrated "sample-to-discovery" model, which includes sample collection, cellular processing, multiomic sequencing, iPSC generation, histology, spatial genomics, bioinformatics, and biobanking. Together, Sampled and AutoGen expand the range of extraction
More news about: Sampled
Oct 21, 2025, 22:48 ET ACROBiosystems•파트너사, 베이징 OrganoAsia 2025 성공적 폐막
오가노이드 시스템은 약물 안전성 평가의 정확성과 효율성 향상에 기여한다. 심장 독성 평가를 위해 연구진은 인간 심장의 구조와 기능을 모사한 심장 오가노이드를 제작하고, 다중 이온 채널 검출과 마이크로전극 어레이(MEA) 기술을 통합하여 약물이 심장 전기생리에 미치는 영향을 정밀하게 평가하고 있다. 또한 신경발달 독성 연구에서는 iPSC 유래 인간 뇌 오가노이드를 이용해 뇌 발달을 모델링하고, 항정신병 약물 할로페리돌이 Notch1 신호전달 경로 억제를 통해 신경 발달을 손상시키는 기전을 규명했으며, 이 독성을 완화할 수 있는 화합물도 확인했다. 김 교수는 오가노이드 기술이 동물 실험 없는 시대의 약물 안전성 평가에서 핵심적
More news about: ACROBiosystems Group
Oct 20, 2025, 06:13 ET Groundbreaking Study in the Journal of Clinical Investigation Advances Cell Therapy for Huntington's Disease Treatment
successfully obtained clinical trial approvals from both the National Medical Products Administration (NMPA) of China and the U.S. FDA, making it the first iPSC-derived autologous cell therapy for Parkinson's disease in China, and the second globally, to enter the clinical stage.
More news about: UniXell Biotechnology
Oct 16, 2025, 08:35 ET Unixell Biotech reported a case study of UX-DA001, an iPSC-derived autologous cell therapy for Parkinson Diseases at MDS Congress 2025
(PD) and other neurological disorders, announced positive 6-month follow-up data from the first patient in its phase 1 clinical trial for UX-DA001, an iPSC-derived autologous cell therapy for PD. These data were presented on October 8th at the International Congress of Parkinson's Disease and Movement Disorders
More news about: UniXell Biotechnology
Oct 15, 2025, 10:00 ET Nikon Small World Honors 51st Annual Photomicrography Competition
WhittakerNational Institutes of HealthNational Institute of Neurological Disorders and StrokeBethesda, Maryland, USAiPSC-derived sensory neurons labelled to show tubulin and actinConfocal, Fluorescence, Image Stacking10X (Objective Lens Magnification)
More news about: Nikon Instruments Inc.
Oct 14, 2025, 09:00 ET iQure Pharma Enters into Research Collaboration with the University of Padova
and cellular techniques for investigating the signaling pathways involved in the disease, and in validating findings in complex systems such as human iPSC-derived cells as well as in vivo models. In recent years, she has deepened her research on the role of glial cells, in particular astrocytes, in Parkinson's
More news about: iQure Pharma Inc.
Oct 13, 2025, 09:00 ET iRegene Therapeutics announced promising NouvNeu001 Phase I clinical data
"Company") is recognized as a biotechnology company pioneering chemically induced allogeneic cell therapy. iRegene's lead product, NouvNeu001, is the 1st iPSC therapy to receive IND approval from both the NMPA and the FDA to treat Parkinson's disease (PD). Recently, NouvNeu001 Phase I clinical data were presented
More news about: iRegene therapeutics
Oct 09, 2025, 07:52 ET Cadenza Bio Announces Peer-Reviewed Study Showing Oral, Brain-Penetrant ERβ Ligands Drive Remyelination and Functional Recovery in MS Models
tolerated and highly selective for ERβ, with no ERα-linked safety concerns observed. In addition, K102 promoted oligodendrocyte maturation in human iPSC-derived cells, reinforcing translational relevance. Study highlights (Preclinical)
More news about: Cadenza Bio, Inc.
Oct 08, 2025, 09:05 ET SIG SAUER Congratulates Mason Lane on his World Championship Win
ammunition, is proud to congratulate Team SIG member Mason Lane on his incredible success at the 2025 International Practical Shooting Confederation (IPSC) Handgun World Shoot held at the Frontier Shooting range in Stilfontein, South Africa. Mason walked away champion of the men's overall production division
More news about: SIG SAUER, Inc.
Oct 07, 2025, 09:00 ET Celaid Therapeutics Raises JPY 1.055 Billion (USD 7.2 Million) in the First Close of its Series B Financing
Collaborative research with AGC Inc. on the expansion and functional evaluation of iPSC-HSPCs Ongoing evaluations of our HSC expansion platform by global pharmaceutical and biotech companies
More news about: Celaid Therapeutics Inc.
Sep 30, 2025, 08:30 ET Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership
it has signed a Letter of Intent (LOI) to acquire select assets from Turn Biotechnologies, Inc. ("Turn"), a leader in induced pluripotent stem cells (iPSC) and cellular reprogramming. The proposed cash and stock transaction is subject to completion of due diligence, execution of a definitive agreement,
More news about: Klotho Neurosciences, Inc.
Sep 29, 2025, 14:15 ET Cell X Technologies and BioLamina enter a collaboration to advance standardization in iPSC-based therapeutics
isoforms (both research-use-only and GMP-compatible formulations) into predefined and optimized automated workflows, the partnership seeks to streamline iPSC culture and differentiation while minimizing operator-dependent variability. "Cell X Technologies is committed to advancing automation
More news about: Cell X Technologies, Inc
Sep 25, 2025, 09:03 ET Aspen Neuroscience Initiates Cohort 3 in ASPIRO Phase 1/2a Trial, Highlighting Commercial Formulation of ANPD001 and Its Transformative Potential for Parkinson's Disease
highest quality personalized cells for the patient.Therapeutic Platform. ANPD001 is an autologous induced pluripotent stem cell (iPSC)-derived DANPC therapy. It is a personalized regenerative cell therapy that uses a patient's own cells, avoiding immune rejection and offering tailored
More news about: Aspen Neuroscience, Inc.
Sep 16, 2025, 07:30 ET Yasir Al-Wakeel Appointed CEO of Vesalius Therapeutics and CEO-Partner of Flagship Pioneering
respond favorably to treatments by targeting novel points of intervention. Using large-scale human genetics, genomics, induced pluripotent stem cell (iPSC) models, and artificial intelligence, the company's Physio-Logic platform genetically validates novel molecular targets to identify causal drivers of
More news about: Flagship Pioneering
Sep 15, 2025, 10:01 ET Made Scientific and Basilard BioTech Announce Technology Partnership to Advance Ex Vivo Gene Delivery for T Cell and iPSC Therapies
state-of-the-art GMP manufacturing facility in Princeton, NJ, to validate and scale the Celletto™ platform across T cell, iPSC processes, and other cell substrates in the future. "We look forward to collaborating with Made Scientific to demonstrate the transformative,
More news about: Made Scientific, Inc.
Sep 12, 2025, 09:30 ET Shineco (SISI) Ignites Growth: $8.7M Tech Deal & Major Singapore Alliance Unleash Dual Engines
2025 /PRNewswire/ -- Shineco Inc. (NASDAQ: SISI) ("Shineco" or the "Company"), a developer and commercializer of induced pluripotent stem cell (iPSC) technology platforms, today announced two major strategic advances. Its subsidiary, Xi'an Dong'ao Health Management Co., Ltd. ("Dong'ao Health"), has
More news about: Shineco,Inc.
Sep 11, 2025, 19:30 ET Companhia Brasileira de Cartuchos realiza Campeonato Expresso 2025
se descobrem. Percebem que têm potencial para competir em níveis maiores, em rankings mais altos, e acabam se identificando com modalidades como o IPSC, o Tiro ao Prato, o Tiro de Precisão ou em Movimento. É justamente esse equilíbrio entre diversão, baixo custo e seriedade, no qual seguimos todos os
More news about: Companhia Brasileira de Cartuchos
Sep 11, 2025, 08:00 ET PhenoVista Biosciences and Carolina Molecular Announce Partnership to Extend Multi-omic Data Access to Clients
models and the latest high-content imaging technologies and data-analysis capabilities. Their diverse repertoire includes working with primary cells, iPSC-derived neurons and glia, and client-engineered lines in a variety of formats. About Carolina Molecular Carolina Molecular is a
More news about: Carolina Molecular
Sep 10, 2025, 09:30 ET Shineco Achieves Mass Production of High-Purity Physical Phospholipids, Breaking Foreign Monopoly and Unlocking Innovation Across Industries
10, 2025 /PRNewswire/ -- Shineco Inc. (NASDAQ: SISI) ("Shineco" or the "Company"), a leading developer of induced pluripotent stem cell (iPSC) technology platforms, today announced that its subsidiary, Fuzhou Meidashan Biotechnology Co., Ltd., has successfully achieved large-scale production
More news about: Shineco,Inc.